[1] Natoli, J. L. et al. (2010) Global prevalence of chronic migraine: a systematic review. Cephalalgia, 30, 599–609.
[1] Gazerani, P. (2020) Migraine and diet. Nutrients, 12 (6), 1658.
[1] Ashina, M. et al. (2021) Migraine: disease characterisation, biomarkers, and precision medicine. Lancet, 397 (10 283), 1496−1504.
[1] Younger, D. S. (2016) Epidemiology of migraine. Neurol. Clin., 34 (4), 849−861
[1] Lipton, R. B., Bigal, M. E., Diamond, M., Freitag, F., Reed, M. L. & Stewart, W. F.; AMPP Advisory Group (2007) Migraine prevalence, disease burden, and the need for preventive therapy. Neurology, 68 (5), 343−349.
[1] Karsan, N. & Goadsby, P. J. (2018) Biological insights from the premonitory symptoms of migraine. Nat. Rev. Neurol., 14 (12), 699−710.
[1] Rattanawong, W., Rapoport, A. & Srikiatkhachorn, A. (2022) Neurobiology of migraine progression. Neurobiol. Pain, 12, 100 094.
[1] Goschorska, M., Gutowska, I., Baranowska-Bosiacka, I., Barczak, K. & Chlubek, D. (2020) The use of antioxidants in the treatment of migraine. Antioxidants (Basel), 9 (2), 116.
[1] Lippi, G., Mattiuzzi, C. & Cervellin, G. (2014) C-reactive protein and migraine. Facts or speculations? Clin. Chem. Lab. Med., 52 (9), 1265−1272.
[1] Rainero, I., Govone, F., Gai, A., Vacca, A. & Rubino, E. (2018) Is migraine primarily a metaboloendocrine disorder? Curr. Pain Headache Rep., 22 (5), 36.
[1] Dodick, D. W. (2018) A phase-by-phase review of migraine pathophysiology. Headache, 58 (Suppl 1), 4−16.
[1] Peck, K. R., Johnson, Y. L. & Smitherman, T. A. (2016) Migraine. Handb. Clin. Neurol.,
138, 283−293.
[1] Bigal, M., Krymchantowski, A. V. & Lipton, R. B. (2009) Barriers to satisfactory migraine outcomes. What have we learned, where do we stand? Headache, 49 (7), 1028−1041.
[1] Sun-Edelstein, C. & Rapoport, A. M. (2016) Update on the pharmacological treatment of
chronic migraine. Curr. Pain Headache Rep., 20 (1), 6.
[1] Sun-Edelstein, C. & Mauskop, A. (2011) Alternative headache treatments: nutraceuticals, behavioral and physical treatments. Headache, 51, 469–483.
[1] Sun-Edelstein, C. & Mauskop, A. (2009) Foods and supplements in the management of
migraine headaches. Clin. J. Pain, 25 (5), 446−452.
[1] Robblee, J. & Starling, A. J. (2019) SEEDS for success: Lifestyle management in migraine. Cleve Clin. J. Med., 86 (11), 741−749.
[1] Marashly, E. T. & Bohlega, S. A. (2017) Riboflavin has neuroprotective potential: focus on Parkinson’s disease and migraine. Front. Neurol., 8, 333.
[1] Thompson, D. F. & Saluja, H. S. (2017) Prophylaxis of migraine headaches with riboflavin: A systematic review. J. Clin. Pharm. Ther., 42 (4), 394−403. doi: 10.1111/jcpt.12548.
[1]Condò, M., Posar, A., Arbizzani, A. & Parmeggiani, A. (2009) Riboflavin prophylaxis in pediatric and adolescent migraine. J. Headache Pain, 10 (5), 361−365. doi: 10.1007/s10194-009-0142-2.
[1]Talebian, A., Soltani, B., Banafshe, H. R., Moosavi, G. A., Talebian, M. & Soltani, S. (2018) Prophylactic effect of riboflavin on pediatric migraine: a randomized, double-blind, placebo-controlled trial. Electron Physician, 10 (2), 6279−6285. doi: 10.19082/6279.
[1]MacLennan, S. C., Wade, F. M., Forrest, K. M., Ratanayake, P. D., Fagan, E. & Antony, J. (2008) High-dose riboflavin for migraine prophylaxis in children: a double-blind, randomized, placebo-controlled trial. J. Child. Neurol., 23 (11), 1300−1304. doi: 10.1177/0883073808318053.
[1]Bruijn, J., Duivenvoorden, H., Passchier, J., Locher, H., Dijkstra, N. & Arts, W. F. (2010) Medium-dose riboflavin as a prophylactic agent in children with migraine: a preliminary placebo-controlled, randomised, double-blind, cross-over trial. Cephalalgia, 30 (12), 1426−1434. doi: 10.1177/0333102410365106.
[1]Condò, M., Posar, A., Arbizzani, A. & Parmeggiani, A. (2009) Riboflavin prophylaxis in pediatric and adolescent migraine. J. Headache Pain, 10 (5), 361−365. doi: 10.1007/s10194-009-0142-2.
[1]Schoenen, J., Lenaerts, M. & Bastings, E. (1994) High-dose riboflavin as a prophylactic treatment of migraine: results of an open pilot study. Cephalalgia, 14 (5), 328−329. doi: 10.1046/j.1468-2982.1994.1405328.
[1]Schoenen, J., Jacquy, J. & Lenaerts, M. (1998) Effectiveness of high-dose riboflavin in migraine prophylaxis. A randomized controlled trial. Neurology, 50 (2), 466−470. doi: 10.1212/wnl.50.2.466.
[1]Rahimdel, A., Zeinali, A., Yazdian-Anari, P., Hajizadeh, R. & Arefnia, E. (2015) Effectiveness of vitamin B2 versus sodium valproate in migraine prophylaxis: a randomized clinical trial. Electron Physician, 7 (6), 1344−1348. doi: 10.14661/1344.
[1]Boehnke, C., Reuter, U., Flach, U., Schuh-Hofer, S., Einhäupl, K. M. & Arnold, G. (2004) High-dose riboflavin treatment is efficacious in migraine prophylaxis: an open study in a tertiary care centre. Eur. J. Neurol., 11 (7), 475−477. doi: 10.1111/j.1468-1331.2004.00813.
[1]Di Lorenzo, C. et al. (2009) Mitochondrial DNA haplogroups influence the therapeutic response to riboflavin in migraineurs. Neurology, 72 (18), 1588−1594. doi: 10.1212/WNL.0b013e3181a41269.
[1]Prousky, J. & Seely, D. (2005) The treatment of migraines and tension-type headaches with intravenous and oral niacin (nicotinic acid): systematic review of the literature. Nutr. J., 4, 3. https://doi.org/10.1186/1475-2891-4-3.
[1]Prousky, J., Millman, C. G. & Kirkland, J. B. (2011) Pharmacologic use of niacin. J. Evid. Based Complement. Alternat. Med., 16 (2), 91−101. doi: 10.1177/2156587211399579.
[1]Prousky, J. & Sykes, E. (2003) Two case reports on the treatment of acute migraine with niacin. Its hypothetical mechanism of action upon calcitonin-gene related peptide and platelets. J. Orthomol. Med., 18, 108−110.
[1]Velling, D. A., Dodick, D. W. & Muir, J. J. (2003) Sustained-release niacin for prevention of migraine headache. Mayo Clin. Proc., 78 (6), 770−771. doi: 10.4065/78.6.770.
[1]Prousky, J. & Seely, D. (2005) The treatment of migraines and tension-type headaches with intravenous and oral niacin (nicotinic acid): systematic review of the literature. Nutr. J., 4, 3.
[1]Peracchi, M., Bamonti Catena, F., Pomati, M., De Franceschi, M. & Scalabrino, G. (2001) Human cobalamin deficiency: alterations in serum tumour necrosis factor-alpha and epidermal growth factor. Eur. J. Haematol., 67 (2), 123−127.
[1]van de Lagemaat, E. E., de Groot, L. C. P. G. M. & van den Heuvel, E. G. H. M. (2019) Vitamin B12 in relation to oxidative stress: a systematic review. Nutrients, 11 (2), 482.
[1]Togha, M., Razeghi Jahromi, S., Ghorbani, Z., Martami, F. & Seifishahpar, M. (2019) Serum vitamin B12 and methylmalonic acid status in migraineurs: a case-control study. Headache, 59 (9), 1492−1503.
[1]Urits, I. et al. (2020) Utilization of B12 for the treatment of chronic migraine. Best Pract. Res. Clin. Anaesthesiol., 34 (3), 479−491.
[1]van der Kuy, P. H., Merkus, F. W., Lohman, J. J., ter Berg, J. W. & Hooymans, P. M. (2002) Hydroxocobalamin, a nitric oxide scavenger, in the prophylaxis of migraine: an open, pilot study. Cephalalgia, 22 (7), 513−519. doi: 10.1046/j.1468-2982.2002.00412.
[1]Calik, M. et al. (2018) The association between serum vitamin B12 deficiency and tension-type headache in Turkish children. Neurol. Sci., 39 (6), 1009−1014. doi: 10.1007/s10072-018-3286-5.
[1]Rainero, I., Vacca, A., Roveta, F., Govone, F., Gai, A. & Rubino, E. (2019) Targeting MTHFR for the treatment of migraines. Expert Opin. Ther. Targets, 23 (1), 29−37.
[1]Liampas, I. et al. (2020) Serum homocysteine, pyridoxine, folate, and vitamin B12 levels in migraine: systematic review and meta-analysis. Headache, 60 (8), 1508−1534.
[1]Liu, L., Yu, Y., He, J., Guo, L., Li, H. & Teng, J. (2019) Effects of MTHFR C677T and A1298C polymorphisms on migraine susceptibility: a meta-analysis of 26 studies. Headache, 59 (6), 891−905. doi: 10.1111/head.13540.
[1]Liampas, I. N. et al. (2020) Pyridoxine, folate and cobalamin for migraine: A systematic review. Acta Neurol. Scand., 142 (2), 108−120. doi: 10.1111/ane.13251.
[1]Lea, R., Colson, N., Quinlan, S., Macmillan, J. & Griffiths, L. (2009) The effects of vitamin supplementation and MTHFR (C677T) genotype on homocysteine-lowering and migraine disability. Pharmacogenet. Genomics, 19 (6), 422−428.
[1]Menon, S. et al. (2012) Genotypes of the MTHFR C677T and MTRR A66G genes act independently to reduce migraine disability in response to vitamin supplementation. Pharmacogenet. Genomics, 22 (10), 741−749.
[1]Menon, S. et al. (2015) Effects of dietary folate intake on migraine disability and frequency. Headache, 55 (2), 301−309. doi: 10.1111/head.12490.
[1]Bütün, A., Nazıroğlu, M., Demirci, S., Çelik, Ö. & Uğuz, A. C. (2015) Riboflavin and vitamin E increase brain calcium and antioxidants, and microsomal calcium-ATP-ase values in rat headache models induced by glyceryl trinitrate. J. Membr. Biol., 248 (2), 205−213.
[1]Ziaei, S., Kazemnejad, A. & Sedighi, A. (2009) The effect of vitamin E on the treatment of menstrual migraine. Med. Sci. Monit., 15 (1), CR16−CR19.
[1]Visser, E. J., Drummond, P. D. & Lee-Visser, J. L. A. (2020) Reduction in migraine and headache frequency and intensity with combined antioxidant prophylaxis (N-acetylcysteine, vitamin E, and vitamin C): a randomized sham-controlled pilot study. Pain Pract., 20 (7), 737−747.
[1]Ghorbani, Z. et al. (2019) Vitamin D in migraine headache: a comprehensive review on literature. Neurol. Sci., 40 (12), 2459−2477. doi: 10.1007/s10072-019-04021-z.
[1]Ghorbani, Z. et al. (2021) The effects of vitamin D3 supplementation on TGF-β and IL-17 serum levels in migraineurs: post hoc analysis of a randomized clinical trial. J. Pharm. Health Care Sci., 7 (1), 9.
[1]Ghorbani, Z. et al. (2020) The effects of vitamin D supplementation on interictal serum levels of calcitonin gene-related peptide (CGRP) in episodic migraine patients: post hoc analysis of a randomized double-blind placebo-controlled trial. J. Headache Pain, 21 (1), 22.
[1]Ghorbani, Z. et al. (2020) Vitamin D3 might improve headache characteristics and protect against inflammation in migraine: a randomized clinical trial. Neurol. Sci., 41 (5), 1183−1192.
[1]Nowaczewska, M., Wiciński, M., Osiński, S. & Kaźmierczak, H. (2020) The role of vitamin D in primary headache-from potential mechanism to treatment. Nutrients, 12 (1), 243. doi: 10.3390/nu12010243.
[1]Gazerani, P. et al. (2019) A randomized, double-blinded, placebo-controlled, parallel trial of vitamin D3 supplementation in adult patients with migraine. Curr. Med. Res. Opin., 35 (4), 715−723. doi: 10.1080/03007995.2018.1519503.
[1]Siniscalchi, A., Lochner, P., Cione, E., Michniewicz, A., Guidetti, V. & Gallelli, L. (2019) Improved efficacy of pregabalin by restoring plasma vitamin D levels in migraine: a case report. Psychopharmacol. Bull., 49 (2), 41−45.
[1]Dolati, S., Rikhtegar, R., Mehdizadeh, A. & Yousefi, M. (2020) The role of magnesium in pathophysiology and migraine treatment. Biol. Trace Elem. Res., 196 (2), 375−383. doi: 10.1007/s12011-019-01931-z.
[1]Kirkland, A. E., Sarlo, G. L. & Holton, K. F. (2018) The role of magnesium in neurological disorders. Nutrients, 10 (6), 730. doi: 10.3390/nu10060730.
[1]Ramadan, N. M., Halvorson, H., Vande-Linde, A., Levine, S. R., Helpern, J. A. & Welch, K. M. (1989) Low brain magnesium in migraine. Headache, 29 (9), 590−593. doi: 10.1111/j.1526-4610.1989.hed2909590.
[1]Sarchielli, P., Coata, G., Firenze, C., Morucci, P., Abbritti, G. & Gallai, V. (1992) Serum and salivary magnesium levels in migraine and tension-type headache. Results in a group of adult patients. Cephalalgia, 12 (1), 21−27.
[1]Assarzadegan, F., Asgarzadeh, S., Hatamabadi, H. R., Shahrami, A., Tabatabaey, A. & Asgarzadeh, M. (2016) Serum concentration of magnesium as an independent risk factor in migraine attacks: a matched case-control study and review of the literature. Int. Clin. Psychopharmacol., 31 (5), 287−292.
[1]Slavin, M., Li, H., Khatri, M. & Frankenfeld, C. (2021) Dietary magnesium and migraine in adults: A cross-sectional analysis of the National Health and Nutrition Examination Survey 2001−2004. Headache, 61 (2), 276−286.
[1]von Luckner, A. & Riederer, F. (2018) Magnesium in migraine prophylaxis-is there an evidence-based rationale? A systematic review. Headache, 58 (2), 199−209.
[1]Demirkaya, S., Vural, O., Dora, B. & Topçuoğlu, M. A. (2001) Efficacy of intravenous magnesium sulfate in the treatment of acute migraine attacks. Headache, 41 (2), 171−177.
[1]Mauskop, A. & Varughese, J. (2012) Why all migraine patients should be treated with magnesium. J. Neural Transm. (Vienna), 119 (5), 575−579.
[1]Baratloo, A., Mirbaha, S., Delavar Kasmaei, H., Payandemehr, P., Elmaraezy, A. & Negida, A. (2017) Intravenous caffeine citrate vs. magnesium sulfate for reducing pain in patients with acute migraine headache; a prospective quasi-experimental study. Korean J. Pain, 30 (3), 176−182.
[1]Kandil, M. et al. (2021) MAGraine: Magnesium compared to conventional therapy for treatment of migraines. Am. J. Emerg. Med., 39, 28−33.
[1]Tayyebi, A., Poursadeghfard, M., Nazeri, M. & Pousadeghfard, T. (2019) Is there any correlation between migraine attacks and iron deficiency anemia? A case-control study. Int. J. Hematol. Oncol. Stem Cell Res., 13 (3), 164−171.
[1]Fallah, R., Zare Bidoki, S. & Ordooei, M. (2016) Evaluation efficacy of ferrous sulfate
therapy on headaches of 5-15 years old iron deficient children with migraine. Iran J. Ped. Hematol. Oncol., 6 (1), 32−37.
[1]Gholamreza-Mirzaee, M., Kheiri, S., Khosravi, Sh., Koshdel, A., Keyvani, Z. & Amini, Z. (2012) Iron therapy and migraine headache. J. Shahrekord Univ. Med. Sci., 13 (6), 56–62 [in Persian].
[1]Meng, S. H. et al. (2021) Association between dietary iron intake and serum ferritin and severe headache or migraine. Front. Nutr., 8, 685 564.
[1]Gonullu, H. et al. (2015) The levels of trace elements and heavy metals in patients with acute migraine headache. J. Pak. Med. Assoc., 65 (7), 694−697.
[1]Silva, M. L. et al. (2022) Decreased plasma levels and dietary intake of minerals in women with migraine. Nutr. Neurosci., 2022, 1−8 [published online ahead of print, Jun 3].
[1]Liu, H. Y., Gale, J. R., Reynolds, I. J., Weiss, J. H. & Aizenman, E. (2021) The multifaceted roles of zinc in neuronal mitochondrial dysfunction. Biomedicines, 9 (5), 489.
[1]Ahmadi, H. et al. (2020) Zinc supplementation affects favorably the frequency of migraine attacks: a double-blind randomized placebo-controlled clinical trial. Nutr. J., 19 (1), 101.
[1]Mazaheri, M., Aghdam, A. M., Heidari, M. & Zarrin, R. (2021) Assessing the effect of zinc supplementation on the frequency of migraine attack, duration, severity, lipid profile and hs-CRP in adult women. Clin. Nutr. Res., 10 (2), 127−139.
[1]Hershey, A. D. et al. (2007) Coenzyme Q10 deficiency and response to supplementation in pediatric and adolescent migraine. Headache, 47 (1), 73−80. doi: 10.1111/j.1526-4610.2007.00652.
[1]Quinzii, C. M. et al. (2010) Reactive oxygen species, oxidative stress, and cell death correlate with level of CoQ10 deficiency. FASEB J., 24 (10), 3733−3743.
[1]Dahri, M., Tarighat-Esfanjani, A., Asghari-Jafarabadi, M. & Hashemilar, M. (2019) Oral coenzyme Q10 supplementation in patients with migraine: Effects on clinical features and inflammatory markers. Nutr. Neurosci., 22 (9), 607−615.
[1]Sazali, S., Badrin, S., Norhayati, M. N. & Idris, N. S. (2021) Coenzyme Q10 supplementation for prophylaxis in adult patients with migraine-a meta-analysis. BMJ Open, 11 (1), e039358. doi: 10.1136/bmjopen-2020-039358.
[1]Parohan, M., Sarraf, P., Javanbakht, M. H., Ranji-Burachaloo, S. & Djalali, M. (2020) Effect of coenzyme Q10 supplementation on clinical features of migraine: a systematic review and dose-response meta-analysis of randomized controlled trials. Nutr. Neurosci., 23 (11), 868−875.
[1]Parohan, M., Sarraf, P., Javanbakht, M. H., Foroushani, A. R., Ranji-Burachaloo, S. & Djalali, M. (2021) The synergistic effects of nano-curcumin and coenzyme Q10 supplementation in migraine prophylaxis: a randomized, placebo-controlled, double-blind trial. Nutr. Neurosci., 24 (4), 317−326. doi: 10.1080/1028415X.2019.1627770.
[1]Gross, E. C., Lisicki, M., Fischer, D., Sándor, P. S. & Schoenen, J. (2019) The metabolic face of migraine − from pathophysiology to treatment. Nat. Rev. Neurol., 15 (11), 627−643.
[1]Cavestro, C., Bedogni, G., Molinari, F., Mandrino, S., Rota, E. & Frigeri, M. C. (2018) Alpha-lipoic acid shows promise to improve migraine in patients with insulin resistance: a 6-month exploratory study. J. Med. Food, 21 (3), 269−273.
[1]Rezaei Kelishadi, M., Alavi Naeini, A., Askari, G., Khorvash, F. & Heidari, Z. (2021) The efficacy of alpha-lipoic acid in improving oxidative, inflammatory, and mood status in women with episodic migraine in a randomised, double-blind, placebo-controlled clinical trial. Int. J. Clin. Pract., 75 (9), e14455.
[1]Traina, G. (2016) The neurobiology of acetyl-L-carnitine. Front. Biosci. (Landmark Ed.), 21 (7), 1314−1329. doi:10.2741/4459
[1]Hagen, K. et al. (2015) Acetyl-l-carnitine versus placebo for migraine prophylaxis: A randomized, triple-blind, crossover study. Cephalalgia, 35 (11), 987−995.
[1]Amini, L., Yaghini, O., Ghazavi, M. & Aslani, N. (2021) L-Carnitine versus propranolol for pediatric migraine prophylaxis. Iran. J. Child. Neurol., 15 (2), 77−86.
[1]Kabbouche, M. A., Powers, S. W., Vockell, A. L., LeCates, S. L. & Hershey, A. D. (2003) Carnitine palmityltransferase II (CPT2) deficiency and migraine headache: two case reports. Headache, 43 (5), 490−495.
[1]Hsu, C. C. et al. (1995) CPEO and carnitine deficiency overlapping in MELAS syndrome. Acta Neurol. Scand., 92 (3), 252−255.
[1]Charleston, L. 4th, Khalil, S. & Young, W. B. (2021) Carnitine responsive migraine headache syndrome: case report and review of the literature. Curr. Pain Headache Rep., 25 (4), 26.
[1]Panconesi, A. (2008) Serotonin and migraine: a reconsideration of the central theory. J. Headache Pain, 9 (5), 267−276.
[1]Nicolodi, M. & Sicuteri, F. (1996) Fibromyalgia and migraine, two faces of the same mechanism. Serotonin as the common clue for pathogenesis and therapy. Adv. Exp. Med. Biol., 398, 373−379.
[1]De Benedittis, G. & Massei, R. (1985) Serotonin precursors in chronic primary headache. A double-blind cross-over study with L-5-hydroxytryptophan vs. placebo. J. Neurosurg. Sci., 29 (3), 239−248.
[1]Ribeiro, C. A. (2000) L-5-Hydroxytryptophan in the prophylaxis of chronic tension-type headache: a double-blind, randomized, placebo-controlled study. For the Portuguese Head Society. Headache, 40 (6), 451−456.
[1]Sanders, A. E., Shaikh, S. R. & Slade, G. D. (2018) Long-chain omega-3 fatty acids and headache in the U.S. population. Prostaglandins Leukot. Essent. Fatty Acids, 135, 47−53.
[1]Sadeghi, O., Maghsoudi, Z., Khorvash, F., Ghiasvand, R. & Askari, G. (2015) The relationship between different fatty acids intake and frequency of migraine attacks. Iran. J. Nurs. Midwifery Res., 20 (3), 334−339.
[1]von Schacky, C. (2021) Importance of EPA and DHA blood levels in brain structure and function. Nutrients, 13 (4), 1074. doi:10.3390/nu13041074.
[1]Maghsoumi-Norouzabad, L., Mansoori, A., Abed, R. & Shishehbor, F. (2018) Effects of omega-3 fatty acids on the frequency, severity, and duration of migraine attacks: a systematic review and meta-analysis of randomized controlled trials. Nutr. Neurosci., 21 (9), 614–623.
[1]Soares, A. A., Louçana, P. M. C., Nasi, E. P., Sousa, K. M. H., Sá, O. M. S. & Silva-Néto, R. P. (2018) A double-blind, randomized, and placebo-controlled clinical trial with omega-3 polyunsaturated fatty acids (OPFA ɷ-3) for the prevention of migraine in chronic migraine patients using amitriptyline. Nutr. Neurosci., 21 (3), 219−223.
[1]Guu, T. W. et al. (2019) International Society for Nutritional Psychiatry Research Practice Guidelines for Omega-3 Fatty Acids in the Treatment of Major Depressive Disorder. Psychother. Psychosom., 88 (5), 263−273.
[1]Clayton, P., Hill, M., Bogoda, N., Subah, S. & Venkatesh, R. (2021) Palmitoylethanolamide: a natural compound for health management. Int. J. Mol. Sci., 22 (10), 5305.
[1]Greco, R. et al. (2022) The endocannabinoid system and related lipids as potential targets for the treatment of migraine-related pain. Headache, 62 (3), 227−240.
[1]Gabrielsson, L., Mattsson, S. & Fowler, C. J. (2016) Palmitoylethanolamide for the treatment of pain: pharmacokinetics, safety and efficacy. Br. J. Clin. Pharmacol., 82 (4), 932−942.
[1]Chirchiglia, D. et al. (2018) Effects of add-on ultramicronized N-palmitol ethanol amide in patients suffering of migraine with aura: a pilot study. Front. Neurol., 9, 674.
[1]Hernández, A. G. (2022) Palmitoylethanolamide-based nutraceutical Calmux® in preventive treatment of migraine. Clin. Neurol. Neurosurg., 218, 107 282.
[1]Andersen, L. P., Gögenur, I., Rosenberg, J. & Reiter, R. J. (2016) The safety of melatonin in humans. Clin. Drug Investig., 36 (3), 169−175.
[1]Kozak, H. H. et al. (2017) Sleep quality, morningness-eveningness preference, mood profile, and levels of serum melatonin in migraine patients: a case-control study. Acta Neurol. Belg., 117 (1), 111−119.
[1]Zielonka, D. (2021) Melatonin secretion in migraine patients: the current state of knowledge. Neurol. Neurochir. Pol., 55 (1), 5−7.
[1]Rios, E. R. et al. (2010) Melatonin: pharmacological aspects and clinical trends. Int. J. Neurosci., 120 (9), 583−590.
[1]Sullivan, D. P. (2022) Furthering the understanding of behavioral aspects of sleep and headaches: another piece of the puzzle. Sleep, 45 (5), zsac012.
[1]Aaltonen, K., Hämäläinen, M. L. & Hoppu, K. (2000) Migraine attacks and sleep in children. Cephalalgia, 20 (6), 580−584.
[1]Long, R., Zhu, Y. & Zhou, S. (2019) Therapeutic role of melatonin in migraine prophylaxis: A systematic review. Medicine (Baltimore), 98 (3), e14099.
[1]Gelfand, A. A., Ross, A. C., Irwin, S. L., Greene, K. A., Qubty, W. F. & Allen, I. E. (2020) Melatonin for acute treatment of migraine in children and adolescents: a pilot randomized trial. Headache, 60 (8), 1712−1721.
[1]Crichton, M. et al. (2022) Orally consumed ginger and human health: an umbrella review. Am. J. Clin. Nutr., 115 (6), 1511−1527.
[1]Chen, L. & Cai, Z. (2021) The efficacy of ginger for the treatment of migraine: A meta-analysis of randomized controlled studies. Am. J. Emerg. Med., 46, 567−571.
[1]Martins, L. B. et al. (2020) Double-blind placebo-controlled randomized clinical trial of ginger (Zingiber officinale Rosc.) in the prophylactic treatment of migraine. Cephalalgia, 40 (1), 88−95.
[1]Martins, L. B., Rodrigues, A. M. D. S., Rodrigues, D. F., Dos Santos, L. C., Teixeira, A. L. & Ferreira, A. V. M. (2019) Double-blind placebo-controlled randomized clinical trial of ginger (Zingiber officinale Rosc.) addition in migraine acute treatment. Cephalalgia, 39 (1), 68−76. doi: 10.1177/0333102418776016.
[1]Delaruelle, Z. et al. (2018) Male and female sex hormones in primary headaches. J. Headache Pain, 19 (1), 117.
[1]Shuster, L. T., Faubion, S. S., Sood, R. & Casey, P. M. (2011) Hormonal manipulation strategies in the management of menstrual migraine and other hormonally related headaches. Curr. Neurol. Neurosci. Rep., 11 (2), 131−138.
[1]Molla, M. D., Hidalgo-Mora, J. J. & Soteras, M. G. (2011) Phytotherapy as alternative to hormone replacement therapy. Front. Biosci. (Schol. Ed.), 3 (1), 191−204.
[1]Burke, B. E., Olson, R. D. & Cusack, B. J. (2002) Randomized, controlled trial of phytoestrogen in the prophylactic treatment of menstrual migraine. Biomed. Pharmacother., 56 (6), 283−288.
[1]Ferrante, F., Fusco, E., Calabresi, P. & Cupini, L. M. (2004) Phyto-oestrogens in the prophylaxis of menstrual migraine. Clin. Neuropharmacol., 27 (3), 137−140.
[1]Dzator, J. S. A., Howe, P. R. C., Coupland, K. G. & Wong, R. H. X. (2022) A randomised, double-blind, placebo-controlled crossover trial of resveratrol supplementation for prophylaxis of hormonal migraine. Nutrients, 14 (9), 1763.
[1]Cámara-Lemarroy, C. R., Rodriguez-Gutierrez, R., Monreal-Robles, R. & Marfil-Rivera, A. (2016) Gastrointestinal disorders associated with migraine: A comprehensive review. World J. Gastroenterol., 22 (36), 8149−8160.
[1]Gonzalez, A., Hyde, E., Sangwan, N., Gilbert, J. A., Viirre, E. & Knight, R. (2016) Migraines are correlated with higher levels of nitrate-, nitrite-, and nitric oxide-reducing oral microbes in the American Gut Project Cohort. mSystems, 1 (5), e00105-16.
[1]Gasbarrini, A. et al. (2000) Association between Helicobacter pylori cytotoxic type I CagA-positive strains and migraine with aura. Cephalalgia, 20, 561–565.
[1]Tunca, A., Türkay, C., Tekin, O., Kargili, A. & Erbayrak, M. (2004) Is Helicobacter pylori infection a risk factor for migraine? A case-control study. Acta Neurol. Belg., 104, 161–164.
[1]Faraji, F., Zarinfar, N., Zanjani, A. T. & Morteza, A. (2012) The effect of Helicobacter pylori eradication on migraine: a randomized, double blind, controlled trial. Pain Physician, 15, 495–498.
[1]Arzani, M. et al. (2020) Gut-brain axis and migraine headache: a comprehensive review. J. Headache Pain, 21 (1), 15.
[1]Sensenig, J., Johnson, M. & Staverosky, T. (2001) Treatment of migraine with targeted
nutrition focused on improved assimilation and elimination. Altern. Med. Rev., 6 (5), 488−494.
[1]de Roos, N. M., Giezenaar, C. G., Rovers, J. M., Witteman, B. J., Smits, M. G. & van Hemert, S. (2015) The effects of the multispecies probiotic mixture Ecologic®Barrier on migraine: results of an open-label pilot study. Benef. Microbes, 6 (5), 641−646.
[1]Martami, F. et al. (2019) The effects of a multispecies probiotic supplement on inflammatory markers and episodic and chronic migraine characteristics: A randomized double-blind controlled trial. Cephalalgia, 39 (7), 841−853.
[1] Tarighat Esfanjani, A., Mahdavi, R., Ebrahimi Mameghani, M., Talebi, M., Nikniaz, Z. & Safaiyan, A. (2012) The effects of magnesium, L-carnitine, and concurrent magnesium-L-carnitine supplementation in migraine prophylaxis. Biol. Trace Elem. Res., 150 (1−3), 42−48.
[1] Maizels, M., Blumenfeld, A. & Burchette, R. (2004) A combination of riboflavin, magnesium, and feverfew for migraine prophylaxis: a randomized trial. Headache, 44 (9), 885−890.
[1]Dib, M. (2008) Optimizing prophylactic treatment of migraine: Subtypes and patient matching. Ther. Clin. Risk Manag., 4 (5), 1061−1078. doi:10.2147/tcrm.s3983.
[1]Barrow, M., Bell, L. & Bell, C. (2020) Transforming personalized nutrition practice. Nutr. Rev., 78 (12), 1046−1051. doi:10.1093/nutrit/nuaa012.
[1]Martin, B. R. & Seaman, D. R. (2015) Dietary and lifestyle changes in the treatment of a 23-year-old female patient with migraine. J. Chiropr. Med., 14 (3), 205−211.